​

Pliant Therapeutics (PLRX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

PLRX Stock Forecast

Pliant Therapeutics (PLRX) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $2.50, with a high of $3.00 and a low of $2.00. This represents a 68.92% increase from the last price of $1.48.

- $4 $8 $12 $16 $20 High: $3 Avg: $2.5 Low: $2 Last Closed Price: $1.48

PLRX Stock Rating

Pliant Therapeutics stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (53.33%), 7 Hold (46.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 15 0 7 8 Strong Sell Sell Hold Buy Strong Buy

PLRX Price Target Upside V Benchmarks

TypeNameUpside
StockPliant Therapeutics68.92%
SectorHealthcare Stocks 30.37%
IndustryBiotech Stocks 73.37%

Price Target Trends

1M3M12M
# Anlaysts-29
Avg Price Target-$2.50$30.78
Last Closing Price$1.48$1.48$1.48
Upside/Downside-68.92%1979.73%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 251111--13
Mar, 252311--16
Feb, 2558---13
Jan, 2558---13
Dec, 2458---13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 03, 2025Stifel Nicolaus$3.00$1.38117.39%102.70%
Mar 03, 2025Leerink Partners$2.00$1.3844.93%35.14%
Sep 13, 2024Ed ArceH.C. Wainwright$38.00$11.84220.95%2467.57%
Sep 09, 2024Faisal KhurshidLeerink Partners$33.00$12.87156.41%2129.73%
May 23, 2024Yasmeen RahimiPiper Sandler$40.00$13.85188.81%2602.70%
May 07, 2024Alex ThompsonStifel Nicolaus$32.00$13.91130.05%2062.16%
May 07, 2024Jeff JonesOppenheimer$48.00$13.79248.08%3143.24%
May 07, 2024Ed ArceH.C. Wainwright$36.00$13.79161.06%2332.43%
May 07, 2024Brian AbrahamsRBC Capital$45.00$13.79226.32%2940.54%
Dec 07, 2022J.P. Morgan$42.00$17.18144.47%2737.84%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 17, 2024Piper SandlerOverweightOverweighthold
Sep 13, 2024H.C. WainwrightBuyBuyhold
Aug 09, 2024H.C. WainwrightBuyBuyhold
Jun 06, 2024CitigroupBuyBuyhold
May 23, 2024Piper SandlerOverweightOverweighthold
May 07, 2024OppenheimerOutperformOutperformhold
May 07, 2024H.C. WainwrightBuyBuyhold
May 07, 2024RBC CapitalOutperformOutperformhold
May 07, 2024CitigroupBuyBuyhold
Mar 01, 2022RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-8 $-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.12$-0.50$-2.89$-2.75$-3.47----
Avg Forecast$-2.17$-2.79$-2.89$-2.89$-3.64$-3.99$-4.06$-3.55$-2.12
High Forecast$-2.17$-2.79$-2.89$-2.87$-3.57$-3.52$-2.95$-1.66$-2.12
Low Forecast$-2.17$-2.79$-2.89$-2.93$-3.70$-5.12$-6.51$-7.29$-2.12
Surprise %-48.39%-82.08%--4.84%-4.67%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$41.82M$7.57M$9.69M$1.58M-----
Avg Forecast$39.43M$7.72M$8.99M$2.29M$90.91K$5.75M$5.71M$63.52M$140.92M
High Forecast$39.43M$7.72M$8.99M$3.56M$94.70K$5.75M$5.71M$63.52M$140.92M
Low Forecast$39.43M$7.72M$8.99M$2.02M$87.12K$5.75M$5.71M$63.52M$140.92M
Surprise %6.04%-1.96%7.71%-31.04%-----

Net Income Forecast

$-450M $-360M $-270M $-180M $-90M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-39.74M$-17.91M$-121.50M$-161.34M$-210.30M----
Avg Forecast$-127.21M$-96.80M$-105.37M$-161.34M$-213.36M$-258.62M$-290.67M$-263.59M$-124.41M
High Forecast$-127.21M$-77.44M$-84.30M$-129.07M$-209.56M$-206.85M$-173.32M$-97.23M$-124.41M
Low Forecast$-127.21M$-116.16M$-126.44M$-193.60M$-217.17M$-300.50M$-382.33M$-428.15M$-124.41M
Surprise %-68.76%-81.50%15.31%--1.43%----

PLRX Forecast FAQ

Is Pliant Therapeutics stock a buy?

Pliant Therapeutics stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 7 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Pliant Therapeutics is a favorable investment for most analysts.

What is Pliant Therapeutics's price target?

Pliant Therapeutics's price target, set by 15 Wall Street analysts, averages $2.5 over the next 12 months. The price target range spans from $2 at the low end to $3 at the high end, suggesting a potential 68.92% change from the previous closing price of $1.48.

How does Pliant Therapeutics stock forecast compare to its benchmarks?

Pliant Therapeutics's stock forecast shows a 68.92% upside, outperforming the average forecast for the healthcare stocks sector (30.37%) and underperforming the biotech stocks industry (73.37%).

What is the breakdown of analyst ratings for Pliant Therapeutics over the past three months?

  • April 2025: 7.69% Strong Buy, 7.69% Buy, 84.62% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 12.50% Strong Buy, 18.75% Buy, 68.75% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 38.46% Strong Buy, 61.54% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Pliant Therapeutics’s EPS forecast?

Pliant Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.99, marking a 14.99% increase from the reported $-3.47 in 2024. Estimates for the following years are $-4.06 in 2026, $-3.55 in 2027, and $-2.12 in 2028.

What is Pliant Therapeutics’s revenue forecast?

Pliant Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $5.75M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $5.71M, followed by $63.52M for 2027, and $140.92M for 2028.

What is Pliant Therapeutics’s net income forecast?

Pliant Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-259M, representing an 22.98% increase from the reported $-210M in 2024. Projections indicate $-291M in 2026, $-264M in 2027, and $-124M in 2028.